Cited 0 times in
Neither hepatic steatosis nor fibrosis is associated with clinical outcomes in patients with intestinal Behçet’s disease
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김도영 | - |
dc.contributor.author | 김범경 | - |
dc.contributor.author | 김승업 | - |
dc.contributor.author | 김태일 | - |
dc.contributor.author | 박수정 | - |
dc.contributor.author | 박재준 | - |
dc.contributor.author | 박준용 | - |
dc.contributor.author | 박지혜 | - |
dc.contributor.author | 안상훈 | - |
dc.contributor.author | 이재승 | - |
dc.contributor.author | 이혜원 | - |
dc.contributor.author | 천재희 | - |
dc.contributor.author | 현혜경 | - |
dc.date.accessioned | 2024-04-11T06:32:05Z | - |
dc.date.available | 2024-04-11T06:32:05Z | - |
dc.date.issued | 2024-04 | - |
dc.identifier.issn | 0954-691X | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/198815 | - |
dc.description.abstract | Background: Behçet's disease (BD) and nonalcoholic fatty liver disease (NAFLD) are chronic inflammatory diseases that share pathogenetic mechanisms. In this study, we investigated whether NAFLD influences the clinical outcomes in patients with intestinal BD. Methods: Patients with intestinal BD and available hepatic steatosis index (HSI) and fibrosis-4 (FIB-4) scores were recruited between 2005 and 2022. An HSI of ≥30 and FIB-4 of ≥1.45 were used to diagnose hepatic steatosis and significant liver fibrosis, respectively. The primary outcomes were intestinal BD-related hospitalization, surgery, emergency room visits, or the first use of corticosteroids, immunomodulators, or biologic agents for intestinal BD. Results: A total of 780 patients with BD were selected. The prevalence of hepatic steatosis and significant liver fibrosis were 72.3% and 8.8%, respectively. Multivariate analysis showed that younger age, prior smoking history, concomitant skin lesions, higher white blood cell count, and lower serum albumin levels were independently associated with an increased risk of clinical relapse (all P < 0.05), whereas hepatic steatosis and significant liver fibrosis were not (hazard ratio [HR] = 1.164, 95% confidence interval [CI] 0.923-1.468; P = 0.199 for hepatic steatosis; HR = 0.982, 95% CI 0.672-1.436; P = 0.927 for significant liver fibrosis). Conclusion: Hepatic steatosis and liver fibrotic burden were not independently associated with clinical outcomes in patients with intestinal BD. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Lippincott Williams And Wilkins | - |
dc.relation.isPartOf | EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Behcet Syndrome* / complications | - |
dc.subject.MESH | Behcet Syndrome* / diagnosis | - |
dc.subject.MESH | Behcet Syndrome* / drug therapy | - |
dc.subject.MESH | Fibrosis | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Intestinal Diseases* | - |
dc.subject.MESH | Liver Cirrhosis / diagnosis | - |
dc.subject.MESH | Liver Cirrhosis / epidemiology | - |
dc.subject.MESH | Liver Cirrhosis / etiology | - |
dc.subject.MESH | Non-alcoholic Fatty Liver Disease* / complications | - |
dc.subject.MESH | Non-alcoholic Fatty Liver Disease* / diagnosis | - |
dc.subject.MESH | Non-alcoholic Fatty Liver Disease* / epidemiology | - |
dc.title | Neither hepatic steatosis nor fibrosis is associated with clinical outcomes in patients with intestinal Behçet’s disease | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Hye Kyung Hyun | - |
dc.contributor.googleauthor | Jihye Park | - |
dc.contributor.googleauthor | Soo Jung Park | - |
dc.contributor.googleauthor | Jae Jun Park | - |
dc.contributor.googleauthor | Tae Il Kim | - |
dc.contributor.googleauthor | Jae Seung Lee | - |
dc.contributor.googleauthor | Hye Won Lee | - |
dc.contributor.googleauthor | Beom Kyung Kim | - |
dc.contributor.googleauthor | Jun Yong Park | - |
dc.contributor.googleauthor | Do Young Kim | - |
dc.contributor.googleauthor | Sang Hoon Ahn | - |
dc.contributor.googleauthor | Seung Up Kim | - |
dc.contributor.googleauthor | Jae Hee Cheon | - |
dc.identifier.doi | 10.1097/meg.0000000000002711 | - |
dc.contributor.localId | A00385 | - |
dc.contributor.localId | A00487 | - |
dc.contributor.localId | A00654 | - |
dc.contributor.localId | A01079 | - |
dc.contributor.localId | A01539 | - |
dc.contributor.localId | A01636 | - |
dc.contributor.localId | A01675 | - |
dc.contributor.localId | A04575 | - |
dc.contributor.localId | A02226 | - |
dc.contributor.localId | A05963 | - |
dc.contributor.localId | A03318 | - |
dc.contributor.localId | A04030 | - |
dc.contributor.localId | A06135 | - |
dc.relation.journalcode | J00821 | - |
dc.identifier.eissn | 1473-5687 | - |
dc.identifier.pmid | 38417062 | - |
dc.identifier.url | https://journals.lww.com/eurojgh/fulltext/2024/04000/neither_hepatic_steatosis_nor_fibrosis_is.12.aspx | - |
dc.contributor.alternativeName | Kim, Do Young | - |
dc.contributor.affiliatedAuthor | 김도영 | - |
dc.contributor.affiliatedAuthor | 김범경 | - |
dc.contributor.affiliatedAuthor | 김승업 | - |
dc.contributor.affiliatedAuthor | 김태일 | - |
dc.contributor.affiliatedAuthor | 박수정 | - |
dc.contributor.affiliatedAuthor | 박재준 | - |
dc.contributor.affiliatedAuthor | 박준용 | - |
dc.contributor.affiliatedAuthor | 박지혜 | - |
dc.contributor.affiliatedAuthor | 안상훈 | - |
dc.contributor.affiliatedAuthor | 이재승 | - |
dc.contributor.affiliatedAuthor | 이혜원 | - |
dc.contributor.affiliatedAuthor | 천재희 | - |
dc.contributor.affiliatedAuthor | 현혜경 | - |
dc.citation.volume | 36 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 445 | - |
dc.citation.endPage | 451 | - |
dc.identifier.bibliographicCitation | EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, Vol.36(4) : 445-451, 2024-04 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.